NO20063681L - Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midler - Google Patents
Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midlerInfo
- Publication number
- NO20063681L NO20063681L NO20063681A NO20063681A NO20063681L NO 20063681 L NO20063681 L NO 20063681L NO 20063681 A NO20063681 A NO 20063681A NO 20063681 A NO20063681 A NO 20063681A NO 20063681 L NO20063681 L NO 20063681L
- Authority
- NO
- Norway
- Prior art keywords
- group
- derivatives
- compounds
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
Abstract
Det beskrives forbindelser med den generelle formel (I) der: m betyr 0,1,2 eller 3; n betyr 0,1,2 eller 3; X betyr et oksygen- eller svovelatom eller en SO- eller S0-gruppe; Ri og Ruavhengig av hverandre betyr et hydrogenatom eller en C_-alkylgruppe, eller Ri og Rsammen danner en -(CH)p-gruppe der p er et helt tall fra I til 5 slik at n + p er et helt tall fra 2 til 5; Rbetyr et hydrogen- eller fluoratom eller en hydroksy-eller metylgruppe; Ri betyr en gruppe med den generelle formel CHRCONHRder Rbetyr et hydrogenatom eller en C.-alkylgrupe og R; betyr en hydrogengruppe eller en C.-alkyl-, C_-cykloalkyl-, C.-cykloalkyl-C.-alkylengruppe; og Y betyr en gruppe som for eksempel er valgt blant fenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tiazolyl, naftyl, kinolinyl, isokinolinyl, ftalazinyl, kinazolinyl, kinoksalinyl, naftyridinyl, cinnolinyl, benzofuranyl, dihydrobenzofuranyl, benzotienyl, dihydrobenzotienyl, indolyl, isoindolyl, indolinyl, benzimidazolyl, benzoksazolyl, benzisoksazolyl, benzotiazolyl, benzisotiazolyl, benzotriazolyl, benzoksadiazolyl, benzotiadiazolyl, idet nevnte gruppe eventuelt er substituert. Forbindelsene kan ha form av en base, et syreaddisjonssalt, et hydrat eller et solvat.Videre beskrives forbindelsenes bruk som terapeutika.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0400389A FR2865205B1 (fr) | 2004-01-16 | 2004-01-16 | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
PCT/FR2005/000028 WO2005077898A1 (fr) | 2004-01-16 | 2005-01-07 | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063681L true NO20063681L (no) | 2006-09-18 |
Family
ID=34707893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063681A NO20063681L (no) | 2004-01-16 | 2006-08-16 | Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midler |
Country Status (29)
Country | Link |
---|---|
US (3) | US7439257B2 (no) |
EP (1) | EP1708994B1 (no) |
JP (1) | JP4705590B2 (no) |
KR (1) | KR101171462B1 (no) |
CN (1) | CN100537534C (no) |
AR (1) | AR047384A1 (no) |
AT (1) | ATE369336T1 (no) |
AU (1) | AU2005212868B2 (no) |
BR (1) | BRPI0506918A (no) |
CA (1) | CA2552565C (no) |
CY (1) | CY1106918T1 (no) |
DE (1) | DE602005001930T2 (no) |
DK (1) | DK1708994T3 (no) |
ES (1) | ES2289701T3 (no) |
FR (1) | FR2865205B1 (no) |
HK (1) | HK1101283A1 (no) |
HR (1) | HRP20070421T3 (no) |
IL (1) | IL176769A (no) |
MA (1) | MA28343A1 (no) |
ME (1) | MEP26408A (no) |
NO (1) | NO20063681L (no) |
NZ (1) | NZ548530A (no) |
PL (1) | PL1708994T3 (no) |
PT (1) | PT1708994E (no) |
RS (1) | RS50518B (no) |
RU (1) | RU2392269C2 (no) |
TW (1) | TWI402067B (no) |
WO (1) | WO2005077898A1 (no) |
ZA (1) | ZA200605698B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
FR2866888B1 (fr) * | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
US7269708B2 (en) * | 2004-04-20 | 2007-09-11 | Rambus Inc. | Memory controller for non-homogenous memory system |
PL1849773T3 (pl) | 2005-02-17 | 2014-03-31 | Astellas Pharma Inc | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
US8197472B2 (en) | 2005-03-25 | 2012-06-12 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
US7918848B2 (en) | 2005-03-25 | 2011-04-05 | Maquet Cardiovascular, Llc | Tissue welding and cutting apparatus and method |
WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
JPWO2008023720A1 (ja) * | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
SI2089417T1 (sl) | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
EP2325182A1 (en) | 2006-12-06 | 2011-05-25 | Glaxosmithkline LLC | Bicyclic compounds and use as antidiabetics |
US7884114B2 (en) * | 2007-08-15 | 2011-02-08 | Glaxo Group Limited | Compounds |
JP2011500634A (ja) * | 2007-10-16 | 2011-01-06 | グラクソ グループ リミテッド | 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体 |
US9402680B2 (en) | 2008-05-27 | 2016-08-02 | Maquet Cardiovasular, Llc | Surgical instrument and method |
US9402679B2 (en) | 2008-05-27 | 2016-08-02 | Maquet Cardiovascular Llc | Surgical instrument and method |
US9968396B2 (en) | 2008-05-27 | 2018-05-15 | Maquet Cardiovascular Llc | Surgical instrument and method |
TW201044234A (en) * | 2009-06-08 | 2010-12-16 | Chunghwa Picture Tubes Ltd | Method of scanning touch panel |
US9955858B2 (en) | 2009-08-21 | 2018-05-01 | Maquet Cardiovascular Llc | Surgical instrument and method for use |
US9000010B2 (en) * | 2010-01-20 | 2015-04-07 | Sanofi | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2308850C (en) * | 1997-11-24 | 2007-07-10 | The Scripps Research Institute | Inhibitors of gap junction communication |
HUP0101419A3 (en) * | 1998-04-16 | 2002-08-28 | Texas Biotechnology Corp Houst | Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them |
FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
EP1389107A4 (en) | 2001-04-27 | 2005-10-12 | Bristol Myers Squibb Co | BISARYLIMIDAZOLYL-FATTY ACID AMIDE-HYDROLASE INHIBITORS |
JP2005516986A (ja) * | 2002-02-08 | 2005-06-09 | ブリストル−マイヤーズ スクイブ カンパニー | (オキシム)カルバモイル脂肪酸アミド加水分解酵素インヒビター |
FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
JP4515911B2 (ja) * | 2002-10-07 | 2010-08-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アナンダミド加水分解の遮断による不安の調節 |
CN1703407A (zh) * | 2002-10-08 | 2005-11-30 | 斯克里普斯研究学院 | 脂肪酸酰胺水解酶抑制剂 |
FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
-
2004
- 2004-01-16 FR FR0400389A patent/FR2865205B1/fr not_active Expired - Fee Related
-
2005
- 2005-01-07 ME MEP-264/08A patent/MEP26408A/xx unknown
- 2005-01-07 RU RU2006129640/04A patent/RU2392269C2/ru not_active IP Right Cessation
- 2005-01-07 PL PL05717376T patent/PL1708994T3/pl unknown
- 2005-01-07 ZA ZA200605698A patent/ZA200605698B/en unknown
- 2005-01-07 PT PT05717376T patent/PT1708994E/pt unknown
- 2005-01-07 CA CA2552565A patent/CA2552565C/fr not_active Expired - Fee Related
- 2005-01-07 DK DK05717376T patent/DK1708994T3/da active
- 2005-01-07 AU AU2005212868A patent/AU2005212868B2/en not_active Ceased
- 2005-01-07 BR BRPI0506918-1A patent/BRPI0506918A/pt active Search and Examination
- 2005-01-07 DE DE602005001930T patent/DE602005001930T2/de active Active
- 2005-01-07 JP JP2006548339A patent/JP4705590B2/ja not_active Expired - Fee Related
- 2005-01-07 RS RSP-2007/0371A patent/RS50518B/sr unknown
- 2005-01-07 WO PCT/FR2005/000028 patent/WO2005077898A1/fr active Application Filing
- 2005-01-07 AT AT05717376T patent/ATE369336T1/de active
- 2005-01-07 ES ES05717376T patent/ES2289701T3/es active Active
- 2005-01-07 NZ NZ548530A patent/NZ548530A/en not_active IP Right Cessation
- 2005-01-07 KR KR1020067016045A patent/KR101171462B1/ko not_active IP Right Cessation
- 2005-01-07 CN CNB2005800050936A patent/CN100537534C/zh not_active Expired - Fee Related
- 2005-01-07 EP EP05717376A patent/EP1708994B1/fr active Active
- 2005-01-11 TW TW094100762A patent/TWI402067B/zh not_active IP Right Cessation
- 2005-01-13 AR ARP050100111A patent/AR047384A1/es active IP Right Grant
-
2006
- 2006-07-10 IL IL176769A patent/IL176769A/en not_active IP Right Cessation
- 2006-07-11 US US11/456,708 patent/US7439257B2/en not_active Expired - Fee Related
- 2006-08-03 MA MA29230A patent/MA28343A1/fr unknown
- 2006-08-16 NO NO20063681A patent/NO20063681L/no not_active Application Discontinuation
-
2007
- 2007-08-23 HK HK07109186.8A patent/HK1101283A1/xx not_active IP Right Cessation
- 2007-09-13 HR HR20070421T patent/HRP20070421T3/xx unknown
- 2007-10-08 CY CY20071101288T patent/CY1106918T1/el unknown
-
2008
- 2008-08-21 US US12/195,906 patent/US7674805B2/en not_active Expired - Fee Related
-
2010
- 2010-01-21 US US12/691,384 patent/US8026258B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063681L (no) | Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midler | |
NO20091551L (no) | Derivater av 4-(2-amino-1-hydroksyetyl)fenyl som agonister for betta-2 adrenergisk reseptor | |
JP2007537275A5 (no) | ||
TNSN06203A1 (en) | Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
RS54629B1 (en) | PYROLIDINONS AS METAP-2-INHIBITORS | |
AR049739A1 (es) | Derivados de aril-piridina | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
SG161221A1 (en) | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | |
NO20090328L (no) | Nye forbindelser 385 | |
AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
HRP20120895T1 (hr) | Imidazokinolini sa imuno-modulacijskim svojstvima | |
NO20050418L (no) | Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet | |
ME01395B (me) | Postupak za izradu (1s)-4,5-dimetoksi-1-(metilaminometil)benzociklobutanai njegovih aditivnih soli kiselina kao i njegov a primena za sintezu ivabradina i njegovih farmaceutski prihvatljivih aditivnih soli kiselina | |
AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
HUP0203836A2 (hu) | 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
NO20070173L (no) | Nye forbindelser | |
NO970349D0 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT inhibitorer | |
RU2009114859A (ru) | Производные бензимидазола в качестве селективных ингибиторов кислотной помпы | |
RU2009122666A (ru) | Производные гетероарилпирролидинил- и пиперидинилкетона | |
DK1585493T3 (da) | Triazinderivater som UV-absorbenter | |
EA200700360A1 (ru) | Новые производные амида гетероциклической карбоновой кислоты | |
NO20070157L (no) | Substituerte diketopiperaziner som oksytocinantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |